AstraZeneca COVID-19 Vaccine Trial May Have Included Outdated Information, Federal Agency Says

Click the image below to enlarge the infographic.
  • Results from the recent AstraZeneca COVID-19 vaccine trial may have included outdated information that provided an incomplete view of the efficacy data, the National Institute of Allergy and Infectious Diseases (NIAID) said early Tuesday
  • The statement came just hours after AstraZeneca announced positive results of phase 3 trials conducted in the U.S.
  • AstraZeneca said the vaccine was found to be safe and 100 percent effective in preventing severe COVID-19 disease
  • But later Monday, the NIAID said it was notified by the Data and Safety Monitoring Board (DSMB), a panel of independent experts that review efficacy and safety data of vaccines in the US, about outdated information included in the study
  • AstraZeneca, in response, said that the results were based on data with a cut-off point of Feb. 17, but it would work with the DSMB to provide the most recent efficacy data within 48 hours
  • The NIAID did not say whether the incomplete data might affect the efficacy and safety profile of the vaccine